301 related articles for article (PubMed ID: 11877480)
21. Generation of TGFβR2(-1) neoantigen-specific HLA-DR4-restricted T cell receptors for cancer therapy.
Plewa N; Poncette L; Blankenstein T
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36822673
[TBL] [Abstract][Full Text] [Related]
22. Synthetic peptides that inhibit binding of the collagen type II 261-273 epitope to rheumatoid arthritis-associated HLA-DR1 and -DR4 molecules and collagen-specific T-cell responses.
Fridkis-Hareli M; Rosloniec EF; Fugger L; Strominger JL
Hum Immunol; 2000 Jul; 61(7):640-50. PubMed ID: 10880734
[TBL] [Abstract][Full Text] [Related]
23. Crystal structure of staphylococcal enterotoxin I (SEI) in complex with a human major histocompatibility complex class II molecule.
Fernández MM; Guan R; Swaminathan CP; Malchiodi EL; Mariuzza RA
J Biol Chem; 2006 Sep; 281(35):25356-64. PubMed ID: 16829512
[TBL] [Abstract][Full Text] [Related]
24. Degeneracy of T cell receptor recognition of an influenza virus hemagglutinin epitope restricted by HLA-DQ and -DR class II molecules.
Jones CM; Lake RA; Lamb JR; Faith A
Eur J Immunol; 1994 May; 24(5):1137-42. PubMed ID: 7514130
[TBL] [Abstract][Full Text] [Related]
25. Molecular dynamics simulations of HLA-DR4 (DRB1*0405) complexed with analogue peptide: conformational changes in the putative T-cell receptor binding regions.
Toh H; Kamikawaji N; Tana T; Sasazuki T; Kuhara S
Protein Eng; 1998 Nov; 11(11):1027-32. PubMed ID: 9876923
[TBL] [Abstract][Full Text] [Related]
26. The class II MHC protein HLA-DR1 in complex with an endogenous peptide: implications for the structural basis of the specificity of peptide binding.
Murthy VL; Stern LJ
Structure; 1997 Oct; 5(10):1385-96. PubMed ID: 9351812
[TBL] [Abstract][Full Text] [Related]
27. Different regions of the N-terminal domains of HLA-DR1 influence recognition of individual peptide-DR1 complexes.
Tuosto L; Karr RW; Fu XT; Olson RR; Cundari E; Piccolella E; Lechler R; Lombardi G
Hum Immunol; 1994 Aug; 40(4):312-22. PubMed ID: 7528190
[TBL] [Abstract][Full Text] [Related]
28. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide.
Stern LJ; Brown JH; Jardetzky TS; Gorga JC; Urban RG; Strominger JL; Wiley DC
Nature; 1994 Mar; 368(6468):215-21. PubMed ID: 8145819
[TBL] [Abstract][Full Text] [Related]
29. Flexibility in T-cell receptor ligand repertoires depends on MHC and T-cell receptor clonotype.
Geluk A; van Meijgaarden KE; Ottenhoff TH
Immunology; 1997 Mar; 90(3):370-5. PubMed ID: 9155643
[TBL] [Abstract][Full Text] [Related]
30. T cell selection and differential activation on structurally related HLA-DR4 ligands.
Gebe JA; Novak EJ; Kwok WW; Farr AG; Nepom GT; Buckner JH
J Immunol; 2001 Sep; 167(6):3250-6. PubMed ID: 11544312
[TBL] [Abstract][Full Text] [Related]
31. Exploring the nature of the H-bonds between the human class II MHC protein, HLA-DR1 (DRB*0101) and the influenza virus hemagglutinin peptide, HA306-318, using the quantum theory of atoms in molecules.
Aray Y; Aguilera-García R; Izquierdo DR
J Biomol Struct Dyn; 2019 Jan; 37(1):48-64. PubMed ID: 29246090
[TBL] [Abstract][Full Text] [Related]
32. Binary and ternary complexes between T-cell receptor, class II MHC and superantigen in vitro.
Seth A; Stern LJ; Ottenhoff TH; Engel I; Owen MJ; Lamb JR; Klausner RD; Wiley DC
Nature; 1994 May; 369(6478):324-7. PubMed ID: 8183371
[TBL] [Abstract][Full Text] [Related]
33. Complementarity-determining region 1 sequence requirements drive limited V alpha usage in response to influenza hemagglutinin 307-319 peptide.
Brawley JV; Concannon P
J Immunol; 2002 Apr; 168(8):3894-901. PubMed ID: 11937544
[TBL] [Abstract][Full Text] [Related]
34. Modulation of promiscuous T cell receptor recognition by mutagenesis of CDR2 residues.
Brawley JV; Concannon P
J Exp Med; 1996 May; 183(5):2043-51. PubMed ID: 8642315
[TBL] [Abstract][Full Text] [Related]
35. Identification of HLA-DR1 beta chain residues critical for binding staphylococcal enterotoxins A and E.
Karp DR; Long EO
J Exp Med; 1992 Feb; 175(2):415-24. PubMed ID: 1370684
[TBL] [Abstract][Full Text] [Related]
36. A structural voyage toward an understanding of the MHC-I-restricted immune response: lessons learned and much to be learned.
Gras S; Burrows SR; Turner SJ; Sewell AK; McCluskey J; Rossjohn J
Immunol Rev; 2012 Nov; 250(1):61-81. PubMed ID: 23046123
[TBL] [Abstract][Full Text] [Related]
37. Overlap of direct and indirect alloreactive T-cell repertoires when MHC polymorphism is limited to the peptide binding groove.
Battaglia M; Gorski J
Hum Immunol; 2002 Feb; 63(2):91-100. PubMed ID: 11821156
[TBL] [Abstract][Full Text] [Related]
38. Accuracy of a structural homology model for a class II histocompatibility protein, HLA-DR1: comparison to the crystal structure.
Nauss JL; Reid RH; Sadegh-Nasseri S
J Biomol Struct Dyn; 1995 Jun; 12(6):1213-33. PubMed ID: 7669268
[TBL] [Abstract][Full Text] [Related]
39. Interactions among polymorphic and conserved residues in MHC class II proteins affect MHC-peptide conformation and T cell recognition.
Tate KM; Lee C; Edelman S; Carswell-Crumpton C; Liblau R; Jones PP
Int Immunol; 1995 May; 7(5):747-61. PubMed ID: 7547702
[TBL] [Abstract][Full Text] [Related]
40. Identification of an altered peptide ligand based on the endogenously presented, rheumatoid arthritis-associated, human cartilage glycoprotein-39(263-275) epitope: an MHC anchor variant peptide for immune modulation.
Boots AM; Hubers H; Kouwijzer M; den Hoed-van Zandbrink L; Westrek-Esselink BM; van Doorn C; Stenger R; Bos ES; van Lierop MJ; Verheijden GF; Timmers CM; van Staveren CJ
Arthritis Res Ther; 2007; 9(4):R71. PubMed ID: 17645792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
